Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction Nationwide
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri, a 300-bed Covenant Health affiliate, and a leading South Texas teaching hospital and Level 1 trauma center. CEO Michael Feldschuh highlighted that strategic investments in sales and marketing are driving growth, with further developments expected in the year's second half.
- Expansion of BVA technology to three new centers.
- Increased adoption of the ezBVA Lab service.
- Projected accelerated sales growth in the second half of the year.
- Strategic investments in sales and marketing yielding strong results.
- None.
The expansion of Daxor Corporation's BVA-100™ Blood Volume Diagnostic into three new centers marks a noteworthy development. The BVA-100™ technology is significant in the medical field for its ability to accurately measure blood volume, which can be important in diagnosing and managing various conditions such as heart failure and shock. The integration of this technology into regional and advanced care centers highlights its growing acceptance and potential to improve patient outcomes. Adoption by facilities such as a regional referral center and a Level 1 trauma center signifies recognition of the tool’s efficacy. This momentum can drive further adoption, positively influencing Daxor's market position.
The company's ezBVA Lab service also indicates a strategic move towards providing faster and more efficient diagnostic results. A CLIA certified facility assures compliance with quality standards, making it a reliable option for healthcare providers. This service could streamline diagnostic processes, reduce wait times for results and ultimately lead to better patient care. However, while early adoption is promising, the long-term impact will depend on continuous positive clinical outcomes and sustained integration in healthcare systems.
From a financial perspective, Daxor’s expansion and increasing market penetration signal potential revenue growth. The addition of new centers adopting their technology can directly translate to increased sales and services revenue. Daxor’s strategic efforts in sales and marketing, yielding tangible results, are encouraging signs for investors. The future outlook, emphasizing further developments in the second half of the year, suggests a strong pipeline that could drive sustained growth. Sales growth often correlates with improved financial performance, although it's essential to monitor cost management to ensure profitability. If the company can maintain its growth trajectory and manage its operational costs effectively, it could result in enhanced shareholder value.
However, it's important to consider potential risks. The healthcare sector can be volatile and changes in regulations, competition, or technological advancements could impact Daxor's market position. Investors should also be cautious of over-reliance on a few key markets or clients, as diversification is vital for long-term stability. Overall, the current expansion and market traction are positive indicators, but continuous evaluation of financial health and market conditions remains necessary.
Daxor's ezBVA Lab Service Emerges as Key Driver for Expansion and Market Penetration
Oak Ridge, TN, July 11, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces the expansion of blood volume analysis (BVA). This growth includes launching a BVA program and increasing adoption of Daxor's ezBVA Lab service - a state-of-the-art CLIA certified facility that provides on-demand, next day blood volume analysis results. The company foresees a strong lineup of developments in the second half of this year, reinforcing its trajectory of accelerated sales growth.
Recent sales wins include:
- Regional referral center for Northeast Arkansas and Southeast Missouri starts a BVA program.
- Covenant Health affiliate, a 300-bed facility, integrates Daxor's ezBVA Lab service.
- Leading South Texas teaching hospital and Level 1 trauma center adopts Daxor's ezBVA Lab service.
"Our unwavering focus on expanding market presence continues to yield strong results. The strategic investments we've made in our sales and marketing efforts are clearly bearing fruit," stated Michael Feldschuh, CEO and President of Daxor. “This growth underscores the increasing recognition of our blood volume analysis technology as a critical tool in improving patient outcomes."
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What recent expansions has Daxor announced for its blood volume analysis (BVA) technology?
What is the ezBVA Lab service offered by Daxor (DXR)?
How is Daxor (DXR) planning to drive growth in the second half of the year?
What impact has the expansion of Daxor 's BVA technology had on market penetration?
